var data={"title":"Meropenem: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Meropenem: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6538?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">see &quot;Meropenem: Drug information&quot;</a> and <a href=\"topic.htm?path=meropenem-patient-drug-information\" class=\"drug drug_patient\">see &quot;Meropenem: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193322\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Merrem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193323\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Meropenem For Injection;</li>\n      <li>Merrem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048505\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Carbapenem</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443862\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection (non-CNS), treatment</b>: Limited data available: For organisms highly susceptible to meropenem, MIC &lt;4 mcg/mL (<i>Red Book </i>[AAP 2015]; Bradley 2017): IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Body weight</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postnatal age (days)</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></td></tr>\n        <tr>\n          <td rowspan=\"3\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 60 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 60 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 8 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated:</b> IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Gestational age</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postnatal age</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;32 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;32 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 8 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis:</b> Limited data available; optimal dose not established: IV: 40 mg/kg/dose every 8 hours (Bradley 2017); duration depends on patient specific factors and pathogen being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Moderately resistant infection</b>\n      <b>s:</b> For organisms with MIC 4 to 8 mcg/mL: Limited data available: GA &gt;30 weeks, PNA &gt;7 days: IV: 40 mg/kg/dose every 8 hours, some suggest as a 4-hour infusion; dosing based on a single-dose pharmacokinetic study (n=38) (van den Anker 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048498\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">see &quot;Meropenem: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection (non-CNS)</b>: Infants, Children, and Adolescents: IV: 20 mg/kg/dose every 8 hours; maximum dose: 1,000 mg/dose (Bradley 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary exacerbation:</b> Limited data available: Infants, Children, and Adolescents: IV: 40 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose (Zobell 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia, empiric treatment:</b> Limited data available: Infants, Children, and Adolescents: IV: 20 mg/kg/dose every 8 hours; maximum dose: 1,000 mg/dose (Bradley 2017; Lehrnbecher 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> <b>Note:</b> IDSA guidelines recommend treatment duration of 4 to 7 days (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 to &lt;3 months:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GA &lt;32 weeks: IV: 20 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GA &ge;32 weeks: IV: 30 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents: IV: 20 mg/kg/dose every 8 hours; maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> Infants (Limited data available &lt;3 months of age), Children, and Adolescents: IV: 40 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose (Bradley 2017); duration of therapy dependent upon pathogen: <i>N. meningitidis</i>, <i>H. influenza:</i> 7 days; <i>S. pneumoniae</i>: 10 to 14 days; aerobic gram-negative bacilli: 21 days (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin</b>\n      <b> and skin structure infection, complicated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants &ge;3 months, Children, and Adolescents: IV: 10 mg/kg/dose every 8 hours; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe or necrotizing infections: Infants, Children, and Adolescents: IV: 20 mg/kg/dose every 8 hours; maximum dose: 1,000 mg/dose (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> IV: 500 to 2,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cholangitis, intra-abdominal infections, complicated:</b> IV: 1,000 mg every 8 hours; <b>Note:</b> 2010 IDSA guidelines recommend treatment duration of 4 to 7 days (provided source controlled). Not recommended for mild to moderate, community-acquired intra-abdominal infections due to risk of toxicity and the development of resistant organisms (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> IV: 2,000 mg every 8 hours; duration of therapy dependent upon pathogen: <i>N. meningitidis</i>, <i>H. influenza:</i> 7 days; <i>S. pneumoniae:</i> 10 to 14 days; aerobic gram-negative bacilli: 21 days (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infection, complicated:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pseudomonas aeruginosa</i>-suspected or confirmed: 1,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pseudomonas aeruginosa</i> not suspected: 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. Some clinicians have used the following (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 20 to 40 mg/kg/dose every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 20 to 40 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 10 to 20 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 10 to 20 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD): Meropenem and metabolite are readily dialyzable: 10 to 20 mg/kg/dose every 24 hours; on dialysis days give dose <b>after</b> hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 10 to 20 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 20 to 40 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 26 to 50 mL/minute: Administer recommended dose based on indication every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 25 mL/minute: Administer one-half recommended dose based on indication every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer one-half recommended dose based on indication every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternative recommendations: </i>\n      <b>Note:</b> Renally adjusted dose recommendations are based on doses of 1 to 2 g every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 50 mL/minute: Administer recommended dose based on indication every 12 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute: Administer recommended dose based on indication every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Meropenem and its metabolites are readily dialyzable: 500 mg every 24 hours. <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Administer recommended dose (based on indication) every 24 hours (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Kuti 2005; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH: Loading dose of 1,000 mg followed by either 500 mg every 8 hours <b>or</b> 1,000 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHD/CVVHDF: Loading dose of 1,000 mg followed by either 500 mg every 6 to 8 hours <b>or</b> 1,000 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Consider giving patients receiving CVVHDF dosages of 750 mg every 8 hours <b>or</b> 1,500 mg every 12 hours (Heintz 2009). Substantial variability exists in various published recommendations, ranging from 1,000 to 3,000 mg/<b>day</b> in 2 to 3 divided doses. One gram every 12 hours achieves a target trough of ~4 mg/L.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193298\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Merrem: 500 mg (1 ea); 1 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea); 1 g/50 mL in NaCl 0.9% (1 ea); 500 mg/50 mL in NaCl 0.9% (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193283\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048508\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Infants &ge;3 months, Children, Adolescents, and Adults: Administer reconstituted solution (up to 1 g) over 3 to 5 minutes; safety data is limited with 40 mg/kg doses up to a maximum of 2 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion: Further dilute reconstituted solution prior to administration</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;3 months: Administer as an IV infusion over 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, Adolescents, and Adults: Administer IV infusion over 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Some studies have demonstrated enhanced pharmacodynamic effects when extending intermittent infusions to 4 hours (van den Anker 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193316\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Freshly prepared solutions should be used. However, constituted solutions maintain satisfactory potency under the conditions described below. Solutions should not be frozen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store intact vials and unactivated Duplex containers at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Unactivated duplex units with foil strip removed from the drug chamber must be protected from light and used within 7 days at room temperature. Once activated, must be used within 1 hour if stored at room temperature or within 15 hours if stored under refrigeration. Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dry powder should be stored at controlled room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection reconstitution: Stability in vial when constituted (up to 50 mg/mL) with:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SWFI: Stable for up to 3 hours at up to 25&deg;C (77&deg;F) or for up to 13 hours at up to 5&deg;C (41&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infusion admixture (1 to 20 mg/mL): Solution is stable when diluted in NS for 1 hour at up to 25&deg;C (77&deg;F) or 15 hours at up to 5&deg;C (41&deg;F). Solutions constituted with dextrose injection 5% should be used immediately. <b>Note:</b> Meropenem stability (admixed with NS at a concentration of 20 mg/mL) at room temperature for &gt;1 hour or under refrigeration for &gt;15 hours is not supported by the manufacturer. Data exist supporting stability (admixed with NS at a concentration of 20 mg/mL) at room temperature for &le;4 hours and under refrigeration &le;24 hours (Patel, 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duplex container: Following reconstitution/activation, use within 1 hour if stored at room temperature or 15 hours refrigerated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048507\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, <i>E. coli</i>, <i>Klebsiella pneumoniae</i>, <i>P. aeruginosa</i>, <i>B. fragilis</i>, <i>B. thetaiotaomicron</i>, and <i>Peptostreptococcus</i> species (FDA approved in all ages); treatment of bacterial meningitis caused by <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i>, and <i>Neisseria meningitidis</i> (FDA approved in pediatric patients ages &ge;3 months); treatment of complicated skin and skin structure infections caused by <i>Staphylococcus aureus</i> (methicillin-susceptible isolates only), <i>Streptococcus pyogenes</i>, <i>S. agalactiae</i>, viridans group streptococci, <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates only), <i>Pseudomonas aeruginosa</i>, <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Bacteroides fragilis</i>, and <i>Peptostreptococcus</i> species (FDA approved in ages &ge;3 months and adults); has also been used for treatment of lower respiratory tract infections, acute pulmonary exacerbations in cystic fibrosis, urinary tract infections, empiric treatment of febrile neutropenia, and sepsis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027563\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Meropenem may be confused with ertapenem, imipenem, metroNIDAZOLE</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193368\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac arrest, cardiac failure, chest pain, hypertension, hypotension, myocardial infarction, peripheral edema, peripheral vascular disease, pulmonary embolism, shock, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, chills, confusion, convulsions (neonates and infants &lt;3 months), delirium, depression, dizziness, drowsiness, hallucination, headache, insomnia, nervousness, pain, paresthesia, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermal ulcer, diaphoresis, pruritus, skin rash (includes diaper-area moniliasis in infants), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypervolemia, hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, enlargement of abdomen, flatulence, gastrointestinal disease, glossitis, intestinal obstruction, nausea, oral candidiasis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria, pelvic pain, urinary incontinence, vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, hypochromic anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, hepatic failure, hyperbilirubinemia (conjugated; neonates and infants &lt;3 months), jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Inflammation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, asthma, cough, dyspnea, hypoxia, pharyngitis, pleural effusion, pneumonia, pulmonary edema, respiratory tract disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agranulocytosis, angioedema, change in platelet count, <i>Clostridium difficile</i> associated diarrhea, decreased hematocrit, decreased hemoglobin, decreased partial thromboplastin time, decreased prothrombin time, decreased white blood cell count, DRESS syndrome, edema at injection site, eosinophilia, epistaxis, erythema multiforme, gastrointestinal hemorrhage, hematuria, hemolytic anemia, hemoperitoneum, hypokalemia, increased blood urea nitrogen, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, injection site reaction, leukocytosis, leukopenia, localized phlebitis, melena, neutropenia, positive direct Coombs test, positive indirect Coombs test, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193305\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to meropenem, other drugs in the same class, or any component of the formulation; patients who have experienced anaphylactic reactions to beta-lactams</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193287\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported (some without a history of previous allergic reactions to beta-lactams).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. Outpatient use may result in paresthesias, seizures, delirium and/or headaches that can impair neuromotor function and alertness; patients should not operate machinery or drive until it is established that meropenem is well tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with creatinine clearance &le;50 mL/minute. Increased seizure risk and thrombocytopenia have been reported in patients with renal  impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions.  Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy.  Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Lower doses (based upon renal function) are often required in the elderly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299674\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193292\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12583&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Meropenem.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193294\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193307\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Incomplete transplacental transfer of meropenem was found using an <i>ex vivo</i> human perfusion model. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048504\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal, hepatic, and hematologic function tests. Observe for changes in bowel frequency. Monitor for signs of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193286\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to several of the penicillin-binding proteins, which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis; bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193304\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Penetrates into most tissues and body fluids including urinary tract, peritoneal fluid, bone, bile, lung, bronchial mucosa, muscle tissue, heart valves (Craig 1997), and CSF (CSF penetration: Neonates and Infants &le;3 months: 70%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates and Infants &le;3 months: Median: ~0.47 L/kg (Smith 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children: 0.3 to 0.4 L/kg (Blumer 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 15 to 20 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; hydrolysis of beta-lactam bond to open beta-lactam form (inactive) (Craig 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates and Infants &le;3 months: Median: 2.7 hours; range: 1.6 to 3.8 hours (Smith 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 3 months to 2 years: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to 12 years and Adults: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Tissue: ~1 hour following infusion except in bile, lung, and muscle; CSF: 2 to 3 hours with inflamed meninges</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~70% as unchanged drug; ~28% inactive metabolite); feces (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates and Infants &le;3 months: 0.12 L/hour/kg (Smith 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: 0.26 to 0.37 L/hour/kg (Blumer 1995)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422265\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Meropenem Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Meropenem-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (1): $26.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/50 mL (1): $19.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Merrem Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $80.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $40.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193310\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Archifar (HR, MT, SG);</li>\n      <li>Bironem (VN);</li>\n      <li>Come (UA);</li>\n      <li>Elpenem (LK);</li>\n      <li>Enem (TH);</li>\n      <li>Eradix (ID);</li>\n      <li>Grambiot (PY);</li>\n      <li>Haizheng Meite (CN);</li>\n      <li>Lanmer (ID);</li>\n      <li>Mabapenem (KR);</li>\n      <li>Madiba (EC);</li>\n      <li>Mapenem (TH);</li>\n      <li>Mecapem (KR);</li>\n      <li>Meflupin (TW);</li>\n      <li>Melopen (TW);</li>\n      <li>Menem IV (PH);</li>\n      <li>Mepem (CN, TW);</li>\n      <li>Mepenan (UA);</li>\n      <li>Mero (TH);</li>\n      <li>Merobac I.V. (CO);</li>\n      <li>Merofen (ID);</li>\n      <li>Merogram (TZ);</li>\n      <li>Meromax (PH);</li>\n      <li>Meronem (AE, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CR, CU, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IS, JM, JO, KE, KW, LB, LR, LT, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, PA, PE, PH, PK, PL, PR, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, TH, TN, TR, TT, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Meronia (TZ);</li>\n      <li>Merop (PH);</li>\n      <li>Meropemed (PE);</li>\n      <li>Meropen (JP, KR, LK, PH);</li>\n      <li>Meropevex (PH);</li>\n      <li>Meroponia (IE);</li>\n      <li>Merosan (ID);</li>\n      <li>Merosayz (UA);</li>\n      <li>Merovex (PH);</li>\n      <li>Meroxi (ID);</li>\n      <li>Merozan (PH);</li>\n      <li>Merozen (PY);</li>\n      <li>Merrem (BB, IT, MX, NZ);</li>\n      <li>Monem (LK, MY, TH);</li>\n      <li>Myron (TW);</li>\n      <li>Nemmed (TH);</li>\n      <li>Newropenem (KR);</li>\n      <li>Opimer (ID);</li>\n      <li>Optinem (AT);</li>\n      <li>Penem (ID);</li>\n      <li>Penomer (LK);</li>\n      <li>Pisapem (EC);</li>\n      <li>Pospenem (KR);</li>\n      <li>Romenem (TH);</li>\n      <li>Ronem (ID);</li>\n      <li>Ropen (PH);</li>\n      <li>Tripenem (ID, MY, PH);</li>\n      <li>Zakster (UA);</li>\n      <li>Zaxter (TH);</li>\n      <li>Zeropenem (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Reed MD, Kearns GL, et al, &ldquo;Sequential, Single-Dose Pharmacokinetic Evaluation of Meropenem in Hospitalized Infants and Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(8):1721-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/7486908/pubmed\" target=\"_blank\" id=\"7486908\">7486908</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Saiman L, Konstan MW, et al, &quot;The Efficacy and Safety of Meropenem and Tobramycin Vs Ceftazidime and Tobramycin in the Treatment of Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis,&quot; <i>Chest</i>, 2005, 128(4):2336-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/16236892/pubmed\" target=\"_blank\" id=\"16236892\">16236892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blummer JL, &ldquo;Pharmacokinetic Determinants of Carbapenem Therapy in Neonates and Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1996, 15(8):733-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/8858691/pubmed\" target=\"_blank\" id=\"8858691\">8858691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley, JS, &ldquo;Meropenem: A New, Extremely Broad Spectrum Beta-lactam Antibiotic for Serious Infections in Pediatrics,&rdquo; <i>Pediatr Infect Dis J</i>, 1997, 16:263-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/9076812 /pubmed\" target=\"_blank\" id=\"9076812 \">9076812 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Sauberan JB, Ambrose PG, et al, &quot;Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate,&quot; <i>Pediatr Infect Dis J</i>, 2008, 27(9):794-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/18645546/pubmed\" target=\"_blank\" id=\"18645546\">18645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Craig WA, &ldquo;The Pharmacology of Meropenem, a New Carbapenem Antibiotic,&rdquo; <i>Clin Infect Dis</i>, 1997, 24(Suppl 2):266-75.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15985760\"></a>Kuti JL, Nicolau DP. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. <i>Chemotherapy</i>. 2005;51(4):211-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/15985760/pubmed\" target=\"_blank\" id=\"15985760\">15985760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Latzin P, Fehling M, Bauernfeind A, et al, &quot;Efficacy and Safety of Intravenous Meropenem and Tobramycin Versus Ceftazidime and Tobramycin in Cystic Fibrosis,&quot; <i>J Cyst Fibros</i>, 2008, 7(2):142-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/17766190/pubmed\" target=\"_blank\" id=\"17766190\">17766190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/28459614/pubmed\" target=\"_blank\" id=\"28459614\">28459614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merrem for injection (meropenem) [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Odio CM, Puig JR, Feris JM, et al, &ldquo;Prospective, Randomized, Investigator-Blinded Study of the Efficacy and Safety of Meropenem vs. Cefotaxime Therapy in Bacterial Meningitis in Children. Meropenem Meningitis Study Group,&rdquo; <i>Pediatr Infect Dis J</i>, 1999, 18(7):581-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/10440432/pubmed\" target=\"_blank\" id=\"10440432\">10440432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel PR, Cook SE, &ldquo;Stability of meropenem in intravenous solutions,&rdquo; <i>Am J Health-Syst Pharm</i>, 1997, 54(4):412-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/9043564/pubmed\" target=\"_blank\" id=\"9043564\">9043564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith PB, Cohen-Wolkowiez M, Castro LM, et al, &ldquo;Populations Pharmacokinetics of Meropenem in Plasma and Cerebrospinal Fluid of Infants With Suspected or Complicated Intra-abdominal Infections, &quot;Pediatr Infect Dis J,&quot; 2011, 30(10):844-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &quot;Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Anker JN, Pokorna P, Kinzig-Schippers M, et al, &quot;Meropenem Pharmacokinetics in the Newborn,&quot; <i>Antimicrob Agents Chemother</i>, 2009, 53(9):3871-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/19581463/pubmed\" target=\"_blank\" id=\"19581463\">19581463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ververs TF, van Dijk A, Vinks SA, et al, &ldquo;Pharmacokinetics and Dosing Regimen of Meropenem in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration,&rdquo; <i>Crit Care Med</i>, 2000, 28(10):3412-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/11057794/pubmed\" target=\"_blank\" id=\"11057794\">11057794</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiseman LR, Wagstaff AJ, Brogden RN, et al, &ldquo;Meropenem. A Review of its Antibacterial Activity, Pharmacokinetic Properties and Clinical Efficacy,&rdquo; <i>Drugs</i>, 1995, 50(1):73-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/7588092/pubmed\" target=\"_blank\" id=\"7588092\">7588092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yildirim I, Aytac S, Ceyhan M, et al, &quot;Piperacillin/Tazobactam Plus Amikacin Versus Carbapenem Monotherapy as Empirical Treatment of Febrile Neutropenia in Childhood Hematological Malignancies,&quot; <i>Pediatr Hematol Oncol</i>, 2008, 25(4):291-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/18484473/pubmed\" target=\"_blank\" id=\"18484473\">18484473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Young DC, Waters CD, et al, &quot;Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: I. Aztreonam and Carbapenems,&quot; <i>Pediatr Pulmonol</i>, 2012, 47(12):1147-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meropenem-pediatric-drug-information/abstract-text/22911974/pubmed\" target=\"_blank\" id=\"22911974\">22911974</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12583 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193322\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193323\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048505\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443862\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048498\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193298\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F193283\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048508\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F193316\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048507\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6027563\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193368\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193305\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193287\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299674\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193292\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193294\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F193307\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048504\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193286\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F193304\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422265\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193310\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12583|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">Meropenem: Drug information</a></li><li><a href=\"topic.htm?path=meropenem-patient-drug-information\" class=\"drug drug_patient\">Meropenem: Patient drug information</a></li></ul></div></div>","javascript":null}